Zhitong Finance App News, Baili Tianheng (688506.SH) announced that the innovative biopharmaceutical T-Bren (HER2 ADC) independently developed by the company has recently completed the first phase III randomized controlled clinical trial comparing T-Bren with doctor-selected chemotherapy in patients with locally advanced or metastatic biliary tract cancer with HER2 expression who failed to be treated with platinum-containing chemotherapy.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.